Autres langues Cadrenal Therapeutics, Inc.

Actions

CVKD

US1276361086

Marché Fermé - Nasdaq Autres places de cotation 21:59:48 29/05/2024			Varia. 5j.	Varia. 1 janv.
0,4125 ^USD	+2,71%		-0,05%	-44,25%

09/05	Cadrenal Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
09/04	Cadrenal Therapeutics reçoit la désignation de médicament orphelin de la FDA pour la tecarfarine dans la prévention de la thromboembolie et de la thrombose chez les patients porteurs d'un DAVG, d'un DAVR, d'un dispositif d'assistance biventriculaire ou d'un cœur artificiel total.	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	23/05
Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update	09/05
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024	11/04
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	09/04
Cadrenal Therapeutics Gets FDA Orphan Drug Designation for Tecarfarin	09/04
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	09/04
Cadrenal Therapeutics Files $100 Million Mixed Shelf; Shares Fall	12/03
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
CADRENAL THERAPEUTICS TO PARTICIPATE AT TECHNOLOGY AND HEART FAILURE THERAPEUTICS CONFERENCE	27/02
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference	26/02
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial	08/02
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer	08/02
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	24/01
Certain Warrants of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20/01
Certain Common Stock of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20/01
Certain Stock Options of Cadrenal Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-JAN-2024.	20/01
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference	04/01
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target	19/12
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cadrenal Therapeutics, Inc.

Actions

CVKD

US1276361086

Autres langues

Filtres